# The Impact of Fexofenadine Hydrochloride on the Prognosis of Patients Post-Acute Myocardial Infarction

Study · id `cardio:ct-nct07381803` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07381803](<https://clinicaltrials.gov/study/NCT07381803>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07381803

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2804 participants.

## Technical summary

Registry record NCT07381803. Randomized; triple masking; primary purpose treatment. Start 2025-01-27 (actual); primary completion 2026-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 2804 participants (planned count; ClinicalTrials.gov record NCT07381803, source copy `cardio:ctgov-nct07381803-2026-08-07`, retrieved 2026-10-26)
- Started: 2025-01-27 (actual) (ClinicalTrials.gov record NCT07381803, source copy `cardio:ctgov-nct07381803-2026-08-07`, retrieved 2026-10-26)
- Primary completion: 2026-12 (anticipated) (ClinicalTrials.gov record NCT07381803, source copy `cardio:ctgov-nct07381803-2026-08-07`, retrieved 2026-10-26)
- Completion: 2027-06 (anticipated) (ClinicalTrials.gov record NCT07381803, source copy `cardio:ctgov-nct07381803-2026-08-07`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07381803, source copy `cardio:ctgov-nct07381803-2026-08-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07381803-2026-08-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Impact of Fexofenadine Hydrochloride on the Prognosis of Patients Post-Acute Myocardial Infarction
- Condition: Zhejiang University
- Intervention (Drug): Fexofenadine 60 Mg Oral Tablet
- Intervention (Drug): Placebo
- Lead sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry lists this organization as the lead sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine (`cardio:org-second-affiliated-hospital-zhejiang-university-school-of-bfd3ac`)

## Provenance

Content hash: 11bceffd667ad7680d3a545c2411fa4b59c770eb5274d1b79b98c9a3f334962b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
